EIKN Company Profile and Key Details

Short-term trend indicators are mixed aligned (SMA20 -7.95%, SMA50 -7.95%, SMA200 -7.95%). The stock’s 14-day RSI is 41.12 (neutral), while the ATR of 1.61 points to higher daily volatility. The stock remains sitting in the mid-range of its 52-week band, trading -21.61% below its high and over 2.67% above its low. Average 10-day trading volume of 413.28 thousand shares is slightly above the 3-month average of 344.51 thousand, indicating heightened recent market interest.

Analyst sentiment is bearish. Analyst rating data shows there are 3 Strong Buy ratings, 1 Buy ratings, 0 Hold ratings, 0 Sell rating and 3 Strong Sell ratings. Price targets range from $34.00 to $5.00. The high target offers 204.66% upside. The low target suggests -55.2% downside. The mean target is $20.00. This offers 79.21% upside. Eikon Therapeutics, Inc. Common Stock earnings surprise history is a mixed track record. The quarter that ended May 11, 2026, missed forecasts by 29.49%. The prior quarter beat by 658.43%. Over the last six quarters, Apple has recorded several small beats. These include 658.43% in March 30, 2026.

Eikon Therapeutics, Inc. Common Stock last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around -$2.82. This means the shares are trading below this model’s fair value.

Eikon Therapeutics, Inc. Common Stock (NASDAQ:EIKN) closed at $11.15 USD, losing -$0.01 (-0.11%) from the previous close of $11.16. The stock is currently mid-range between its 52-week high and low $7.90 and $17.40. With a market capitalization of about $32.90 million, Eikon Therapeutics, Inc. Common Stock is classified as a micro-cap and shows lower-than-market volatility (beta ~0.00). Key stats such as the average daily volume over the past year has been around 454.03 thousand shares, volume is running light vs its 52-week average. Headquartered in Millbrae, CA, Eikon Therapeutics, Inc. Common Stock operates in the Healthcare sector and the Biotechnology industry. Led by CEO Roger Perlmutter, the company employs approximately 484 people and listed since February 05, 2026. Eikon Therapeutics, Inc., operates as a clinical biopharmaceutical company in the United States.

Our AI price prediction model suggests that Eikon Therapeutics, Inc. Common Stock stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 3-Month Outlook: Projected rise of 21.06%, reaching $13.51 by August 19, 2026, with a range of $13.39 to $13.63. 1-Year Outlook: Projected loss of -73.48%, with price at $2.96 by May 21, 2027, within a range of $2.79 to $3.15.

currently trading near 52-week highs band. Valuation shows Eikon Therapeutics, Inc. Common Stock trading at a premium to the broader market with a P/E of -3.75. Analyst sentiment is cautious, with the majority of ratings in Underperform territory and a mean price target of $20.00, suggesting 79.21% upside.

Eikon Therapeutics, Inc. Common Stock trades at a P/E ratio of -3.75, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 1.11 suggesting the stock is closer to book value. The P/FCF stands at -0.25, also below market averages.